Small molecule induced STING degradation facilitated by the HECT ligase HERC4
- Nat Commun. 2024 May 29;15(1):4584. doi: 10.1038/s41467-024-48922-w.
- 1. Novartis BioMedical Research, Basel, Switzerland. [email protected].
- 2. Novartis BioMedical Research, Basel, Switzerland.
- 3. Amsterdam UMC location Vrije Universiteit Amsterdam, Molecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, De Boelelaan, 1117, Amsterdam, The Netherlands.
- 4. Monte Rosa Therapeutics, Basel, Switzerland.
- 5. Novartis BioMedical Research, Cambridge, MA, USA.
- 6. Vector Biology, Cambridge, MA, USA.
Stimulator of interferon genes (STING) is a central component of the cytosolic nucleic acids sensing pathway and as such master regulator of the type I interferon response. Due to its critical role in physiology and its' involvement in a variety of diseases, STING has been a focus for drug discovery. Targeted protein degradation (TPD) has emerged as a promising pharmacology for targeting previously considered undruggable proteins by hijacking the cellular ubiquitin Proteasome system (UPS) with small molecules. Here, we identify AK59 as a STING degrader leveraging HERC4, a HECT-domain E3 Ligase. Additionally, our data reveals that AK59 is effective on the common pathological STING mutations, suggesting a potential clinical application of this mechanism. Thus, these findings introduce HERC4 to the fields of TPD and of compound-induced degradation of STING, suggesting potential therapeutic applications.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: STING